<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04243889</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-1051</org_study_id>
    <nct_id>NCT04243889</nct_id>
  </id_info>
  <brief_title>Early Feasibility Study: Fetoscopic NEOX Cord 1K® Myelomeningocele (MMC) Repair</brief_title>
  <official_title>Early Feasibility Study of Fetoscopic Myelomeningocele Repair Using a Cryopreserved Human Umbilical Cord Allograft (NEOX Cord 1K®) as a Meningeal Patch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To fetoscopically use cryopreserved human umbilical cord allografts, named NEOX Cord 1K®, as&#xD;
      a spinal cord cover of myelomeningocele spina bifida defects. This procedure will be&#xD;
      performed to create a watertight seal covering over the spinal cord in order to decrease the&#xD;
      incidence rates of postnatal morbidities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with successful fetoscopic repair of the defect using NEOX Cord 1K®</measure>
    <time_frame>Immediately after repair procedure</time_frame>
    <description>A digital image of the fetal repair site will be captured during and immediately after the repair. The images will be sent to three independent blinded neurosurgeons for review of successful closure of the defect. More than best of three votes will be considered as the result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with intact repair of the defect, defined as no cerebrospinal fluid leakage and no dehiscence at the repair site.</measure>
    <time_frame>Birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with intact repair of the defect as defined as no cerebrospinal fluid leakage and no dehiscence at the repair site.</measure>
    <time_frame>12 months ± 2 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of Arnold-Chiari malformation II</measure>
    <time_frame>birth discharge, 1 month + 30 days, 12 ± 2 months, and 60-66 months post birth</time_frame>
    <description>Assessment of Arnold-Chiari malformation II as measured by MRI of head</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with absence of brain stem kinking as assessed by MRI evaluation.</measure>
    <time_frame>birth-discharge, 1 month + 30 days, 12 ± 2 months, and 60-66 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with lower extremity motor and sensory levels exceeding the anatomical level of the lesion by ≥ 2 segments.</measure>
    <time_frame>birth-discharge, 1 month + 30 days, 12 ± 2 months, 30-36 months and 60-66 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients who can ambulate with or without the use of orthotics or devices.</measure>
    <time_frame>30-36 months and 60-66 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with no spinal cord tethering as assessed by a lumbar spine MRI.</measure>
    <time_frame>birth-discharge, 1 month + 30 days, 12 ± 2 months, and 60-66 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with absence of syringomyelia as assessed by an MRI.</measure>
    <time_frame>12 ± 2 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patient with the absence of an epidermoid cyst at the repair site, determined by MRI.</measure>
    <time_frame>birth-discharge, 1 month + 30 days, 12 ± 2 months, and 60-66 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients needing de-tethering surgery before the 12 month ± 2 month visit as clinically indicated.</measure>
    <time_frame>12 ± 2 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Developmental motor scales as assessed by the Bayley IV test.</measure>
    <time_frame>30-36 months follow up post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adaptive behavior as assessed by the Vineland Adaptive Behavior Scales III</measure>
    <time_frame>30-36 months and 60-66 months post delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Achievement as measured by the Woodcock-Johnson IV Test of Achievement test</measure>
    <time_frame>60-66 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assess brain stem function, as measured by the child's swallowing profile</measure>
    <time_frame>12 ± 2 months; 30-36 months and 60-66 months post birth</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Urodynamic function assessments</measure>
    <time_frame>12 ± 2 months, 30-36 months and 60-66 months post birth</time_frame>
    <description>Objective measures of the function of the lower urinary tract by evaluating post-void residual urine</description>
  </other_outcome>
  <other_outcome>
    <measure>Bowel function assessments bowel movements.</measure>
    <time_frame>12 ± 2 months, 30-36 months and 60-66 months post birth</time_frame>
    <description>Bowel function as assessed by observation of neurogenic bowel incontinence or constipation</description>
  </other_outcome>
  <other_outcome>
    <measure>Verbal and non-verbal intelligence as measured by the Kaufman Brief Intelligence Test 2 (KBIT-2)</measure>
    <time_frame>60-66 months post delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Manual dexterity and bimanual coordination as determined by the Purdue Pegboard test</measure>
    <time_frame>60-66 months post delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Executive function testing as measured by the Behavior Rating Inventory of Executive Function 2 (BRIEF2) test</measure>
    <time_frame>60-66 months post delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Visual motor integration as assessed by the Beery Visual-Motor Integration test</measure>
    <time_frame>60-66 months post delivery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life as assessed by the Parkin Spina Bifida Health-Related Quality of Life questionnaire</measure>
    <time_frame>60-66 months post delivery</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Spina Bifida</condition>
  <condition>Myelomeningocele</condition>
  <arm_group>
    <arm_group_label>NEOX Cord 1K applied fetoscopically</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NEOX Cord 1K applied fetoscopically</intervention_name>
    <description>Under general anesthesia and tocolysis, in-utero repair starts with a laparotomy, followed by exteriorization of the uterus and external cephalic version to position the fetus. Uterine entry will be accessed using 3 cannulas, followed by heated-humidified carbon dioxide insufflation for visualization. Fetoscopically, the placode will be dissected and the lesion repaired. NEOX Cord 1K®, a cryopreserved human umbilical cord patch, will be used for meningeal closure over the spinal cord, followed by closure of the fetal skin layer. Next, the carbon dioxide will be removed and replaced with amniotic fluid or with Lactated Ringers Solution. Finally, the fetoscopic hysterotomy sites will be sutured, and the laparotomy site closed in multiple layers.</description>
    <arm_group_label>NEOX Cord 1K applied fetoscopically</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Maternal inclusion criteria:&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Gestational age at screening is 19 to 25 5/7 weeks and gestational age at surgery is&#xD;
             22 to 25 6/7 weeks&#xD;
&#xD;
          -  Maternal age: 18 years and older&#xD;
&#xD;
          -  Body mass index &lt; 40 kg/m2&#xD;
&#xD;
          -  No preterm birth risk factors (short cervix, history of previous preterm delivery)&#xD;
&#xD;
          -  No previous uterine incision in the active uterine segment&#xD;
&#xD;
          -  Willing to undergo an open fetal repair if the fetoscopic approach is unsuccessful&#xD;
&#xD;
        Fetal inclusion criteria:&#xD;
&#xD;
          -  Spina bifida myelomeningocele defect between T1 to S1 vertebral levels&#xD;
&#xD;
          -  Chiari II malformation&#xD;
&#xD;
          -  No evidence of kyphosis (curved spine)&#xD;
&#xD;
          -  No major life-threatening fetal anomaly unrelated to spina bifida&#xD;
&#xD;
          -  Normal karyotype, or normal CMA, or a CMA with variants of unknown significance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Maternal exclusion criteria:&#xD;
&#xD;
          -  Non-resident of the United States&#xD;
&#xD;
          -  Multifetal pregnancy&#xD;
&#xD;
          -  Poorly controlled insulin-dependent pregestational diabetes&#xD;
&#xD;
          -  Poorly controlled A2DM insulin-dependent diabetes&#xD;
&#xD;
          -  Current or planned cerclage or documented history of an incompetent cervix&#xD;
&#xD;
          -  Placenta previa or placental abruption&#xD;
&#xD;
          -  Short cervix of &lt; 20 mm&#xD;
&#xD;
          -  Obesity as defined by a body mass index of &gt; 40 kg/m2&#xD;
&#xD;
          -  Previous spontaneous singleton delivery prior to 37 weeks&#xD;
&#xD;
          -  Maternal-fetal Rh isoimmunization, Kell sensitization, or a history of neonatal&#xD;
             alloimmune thrombocytopenia&#xD;
&#xD;
          -  HIV or Hepatitis-B positive status&#xD;
&#xD;
          -  Known Hepatitis-C positivity&#xD;
&#xD;
          -  Uterine anomaly such as large or multiple fibroids or a mullerian duct abnormality&#xD;
             that is diagnosed via imaging prior to surgery, which that are unavoidable during&#xD;
             surgery&#xD;
&#xD;
          -  Other medical conditions which are contraindication to surgery or general anesthesia&#xD;
&#xD;
          -  Patient does not have a support person&#xD;
&#xD;
          -  Inability to comply with the travel and follow-up requirements of the trial&#xD;
&#xD;
          -  Patient does not meet psychosocial standardized assessment criteria&#xD;
&#xD;
          -  Participation in this or another intervention study that influences maternal and fetal&#xD;
             morbidity and mortality&#xD;
&#xD;
          -  Maternal hypertension&#xD;
&#xD;
          -  Zika virus positivity&#xD;
&#xD;
          -  Allergy/history of drug reaction to Amphotericin B&#xD;
&#xD;
        Fetal exclusion criteria:&#xD;
&#xD;
          -  Major fetal anomaly not related to spina bifida&#xD;
&#xD;
          -  Kyphosis in the fetus of 30 degrees or more&#xD;
&#xD;
          -  Ventriculomegaly greater than 15 mm and no movements noted at hip and knee joints&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramesha Papanna, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramesha Papanna, MD, MPH</last_name>
    <phone>(713) 500-6423</phone>
    <email>Ramesha.Papanna@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeannine Garnett, PhD</last_name>
    <phone>(713) 486-6557</phone>
    <email>Jeannine.Garnett@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramesha Papanna, MD, MPH</last_name>
      <phone>713-500-6423</phone>
      <email>Ramesha.Papanna@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeannine Garnett, PhD</last_name>
      <phone>(713) 486-6557</phone>
      <email>Jeannine.Garnett@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Ramesha Papanna</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Neox Cord 1K</keyword>
  <keyword>Fetoscopic repair</keyword>
  <keyword>Cryopreserved human umbilical cord</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Dysraphism</mesh_term>
    <mesh_term>Meningomyelocele</mesh_term>
    <mesh_term>Spina Bifida Cystica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

